Collectively, exogenous treatment with IL-6 induced proliferation, invasion and VEGF production of ovarian cancer cells, even though they do not express IL-6, and co-treatment with soluble IL-6R was not required. This evidence concerns the gene VEGFA and ovarian cancer.